Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The entry "novel transcript, antisense to SLC38A6" refers to a predicted non-coding RNA transcribed antisense to the SLC38A6 gene, often annotated as LOC101927756 (ENSG00000307460)[6]. No experimental data are available to define its sequence, function, tissue expression, or role in physiology or disease. All current biological, molecular, and disease associations relate to the canonical SLC38A6 gene, a solute carrier family transporter regulating glutamine and glutamate balance at neuronal synapses and implicated in cancer metabolism[1][2][3][6]. The antisense transcript has not been validated as a therapeutic target, nor is it recognized in any protein, receptor, enzyme, or transporter classification scheme.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to solute carrier family 38 member 6.